1

FinnGen enters the next phase, focusing on disease mechanisms and disease progression, with 52 M€ of new funding.

FinnGen brings together the nation-wide network of Finnish biobanks.

Every Finn can be a part of the FinnGen study by giving a biobank consent.
Samples available
629 000
Samples needed by 2023: 520 000
Current data freeze
520 210
combined genotype and health registry data

Samples from biobanks

The FinnGen study will utilise samples collected by a nationwide network of Finnish biobanks. The study is based on combining genome information with digital health care data from national health registries.

Take part

Samples are needed from all over Finland in the thousands, because solutions in the field of personalized healthcare can be found only by looking at large masses. Every Finn can be a part of the FinnGen study by giving a biobank consent.

Everybody benefits

The genome data produced during the project will be owned by the Finnish biobanks, and remain available for researcher purposes. The medical breakthroughs that arise from the project will eventually benefit health care systems and patients globally.

Collaboration is the key

The collaborative nature of the FinnGen research project is exceptional compared to many other studies. The study involves all the same actors as drug development. With this open cooperation, we hope to speed up the emergence of new innovations.

Data freeze 9 results and summary statistics now available!

Results can be browsed online using the FinnGen web browser and the summary statistics downloaded
This data freeze consists of >377,200 individuals, almost 20.2 M variants and 2,272 disease endpoints. To get more information about how to access the results and summary statistics, please follow this link:
Birches with the text "New FinnGen GWAS results".

News

The FinnGen research consortium has successfully collected and generated genomic data from 500,000 individuals. Now, the project will continue its search for genetic clues to disease progression and explore the biological mechanism of the genetic signals uncovered in the first stages of the project.
New results from the FinnGen research consortium demonstrate the undeniable benefits of Finnish health research environment for genomic research. Among the wealth of novel genetic discoveries are previously unknown genetic risk factors for many debilitating diseases. These findings have potential to facilitate the development of new therapies.